Trials / Completed
CompletedNCT00099242
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,040 (planned)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rivastigmine transdermal patch |
Timeline
- Start date
- 2003-11-01
- Completion
- 2006-01-01
- First posted
- 2004-12-10
- Last updated
- 2017-10-13
Locations
75 sites across 21 countries: United States, Chile, Czechia, Denmark, Finland, Germany, Guatemala, Israel, Italy, Mexico, Norway, Peru, Poland, Portugal, Puerto Rico, Russia, Slovakia, South Korea, Sweden, Taiwan, Venezuela
Source: ClinicalTrials.gov record NCT00099242. Inclusion in this directory is not an endorsement.